Evidence map›Paper›PMID 34820771›Full record

Trial reportJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2022

Anti-inflammatory effect of rosuvastatin in patients with HIV infection: An FDG-PET pilot study.

Kevin E Boczar, Elliot Faller, Wanzhen Zeng, Jerry Wang, Gary R Small, Vicente F Corrales-Medina, Robert A deKemp, Natalie C Ward, Rob S B Beanlands, Paul MacPherson and 1 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. [EJNMMI research · 2026
    Review
  3. [EJNMMI research · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2022: positron emission tomography, computed tomography, and magnetic resonance.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Review
  12. Multi-modality imaging: Bird's eye view from the 2020 American Heart Association Scientific Sessions.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Kevin E BoczarDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Elliot FallerThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Wanzhen ZengThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Jerry WangDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Gary R SmallDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Vicente F Corrales-MedinaThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Robert A deKempDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Natalie C WardSchool of Public Health, Curtin University, Perth, Australia.
Rob S B BeanlandsDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Paul MacPherson *The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Girish Dwivedi *Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada. girish.dwivedi@perkins.uwa.edu.au.
University of Ottawa · CAOttawa Hospital · CACurtin University · AUOttawa Hospital Research InstituteUniversity of Western Australia · AU

Funding

CIHR
6 · The paper itself

Abstract

aimsThis study aimed to evaluate markers of systemic as well as imaging markers of inflammation in the ascending aorta, bone marrow, and spleen measured by 18F-FDG PET/CT, in HIV+ patients at baseline and following therapy with rosuvastatin. METHODS AND

resultsOf the 35 HIV+ patients enrolled, 17 were randomized to treatment with 10 mg/day rosuvastatin and 18 to usual care for 6 months. An HIV- control cohort was selected for baseline comparison of serum inflammatory markers and monocyte markers of inflammation. 18F-FDG-PET/CT imaging of bone marrow, spleen, and thoracic aorta was performed in the HIV+ cohort at baseline and 6 months. While CD14++CD16- and CCR2 expressions were reduced, serum levels of IL-7, IL-8, and MCP-1 were elevated in the HIV+ population compared to the controls. There was a significant drop in FDG uptake in the bone marrow (TBR

conclusionsHIV+ patients had significantly markers of systemic inflammation including monocyte activation. Treatment with low-dose rosuvastatin in the HIV+ cohort significantly reduced bone marrow, spleen and thoracic aortic FDG uptake.

Indexed as

Fluorodeoxyglucose F18HIV InfectionsAnti-Inflammatory AgentsBiomarkersHumansInflammationPilot ProjectsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRosuvastatin CalciumAnti-Inflammatory AgentsBiomarkersFluorodeoxyglucose F18RadiopharmaceuticalsRosuvastatin CalciumAtherosclerosisCardiovascular riskFDG-PET/CTHIVInflammationRosuvastatin

Identifiers

PMID34820771
OpenAlexW3216847977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.